Peroxisome proliferator-activated receptors (PPARs) are involved in energy expenditure, regulation of inflammatory processes, and cellular protection in peripheral tissues. Among the different types of PPARs, PPARb is the only one to be widely expressed in cortical neurons. Using PPARb knockout (KO) mice, we report here a detailed investigation of the role of PPARb in cerebral ischemic damage, associated inflammatory and antioxidant processes as well as food intake regulation after middle cerebral artery occlusion (MCAO). The PPARb KO mice had a two-fold increase in infarct size compared with wild-type (WT) mice. Brain oxidative stress was dramatically enhanced in these KO mice, as documented by an increased content of malondialdehyde, decreased levels of glutathione and manganese superoxide dismutase, and no induction of uncoupling protein 2 (UCP2) mRNA. Unlike WT mice, PPARb KO mice showed a marked increase of prooxidant interferon-gamma but no induction of nerve growth factor and tumor necrosis factor alpha after MCAO. In WT mice, MCAO resulted in inflammation-specific transient hyperphagia from day 3 to day 5 after ischemia, which was associated with an increase in neuropeptide Y (NPY) mRNA. This hyperphagic phase and NPY mRNA induction were not observed in PPARb KO mice. Furthermore, our study also suggests for the first time that UCP2 is involved in MCAO food intake response. These data indicate that PPARb plays an important role in integrating and regulating central inflammation, antioxidant mechanisms, and food intake after MCAO, and suggest that the use of PPARb agonists may be of interest for the prevention of central ischemic damage.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily (Kersten et al, 2000) . Several classes of PPARs have been identified, namely PPARa, PPARb, and PPARg, and the latter consists of two isoforms, PPARg1 and PPARg2 (Kersten et al, 2000) . Previous studies have shown that PPARs are expressed differentially in tissues, PPARa being most abundant in the liver and PPARg in adipose tissue, the pancreas, and phagocytes . These two PPARs show a less wide tissue distribution than PPARb, also called PPARd, which is expressed in the lung, liver, kidney, spleen adipocytes, neurons, and oligodendrocytes (Cullingford et al, 1998) . Prior work has documented the central role of PPARs in glucose and lipid metabolism (Kersten et al, 2000) . Peroxisome proliferatoractivated receptors have been associated with energy expenditure by regulating the expression of mitochondrial uncoupling proteins (UCPs) (Evans et al, 2004; Sell et al, 2004) . In particular, PPARa and PPARg have been shown to modulate UCP1, which participates in the control of thermogenesis in brown adipose tissue . Besides these main effects, both in vitro and animal studies indicate that PPARs may control the expression of genes implicated in inflammatory responses and consequently alter cytokine production and cell recruitment to the inflammatory site (Hornung et al, 2001) . For instance, PPARa knockout (KO) mice displayed a long-lasting inflammatory response to lipopolysaccharide stimulation (Delerive et al, 1999) , and PPARa activation results in the repression of inflammatory cytokine production in different cell types (Delerive et al, 2001) . In macrophages, PPARg activation is thought to inhibit cytokine production (Ricote et al, 1998; Greene et al, 2000) , whereas PPARb negatively regulates specific subsets of genes that are activated by T helper 1 cytokines (Welch et al, 2003) . In addition, PPARb induction by inflammatory stimuli may suppress keratinocyte apoptosis during epidermal injury (Tan et al, 2004) .
Despite this progress in the understanding of the function of PPARs, their role in central nervous system pathologies remains unclear. Recent evidence suggests that activation of PPARa receptor with selective agonists may confer neuroprotection after focal cerebral ischemia (Deplanque et al, 2003) . In contrast, the role of PPARb, which is abundantly expressed throughout the murine brain (Woods et al, 2003) , remains obscure. Among the main biologic phenomena thought to be influenced by PPAR activation, cytokine-mediated inflammatory processes and activation of antioxidant mechanisms are of key importance for cell damage after acute cerebral ischemia. In this context, tumor necrosis factor alpha (TNFa) and interferon-gamma (IFNg) are known to favor inflammatory processes (Blasko et al, 2001; Li et al, 2001) , whereas nerve growth factor (NGF) may protect against inflammatory damage (Guegan et al, 1998) by inducing the activation of antioxidant mechanisms, such as an increase in manganese superoxide dismutase (MnSOD) (Guegan et al, 1999) , glutathione (GSH) (Guegan et al, 1998) , and/or UCP2 (de Bilbao et al, 2004) . Using middle cerebral artery occlusion (MCAO) in mice, the present study explores the effects of a genetic PPARb deficiency on brain infarct size, activation of the associated inflammatory and antioxidant processes as well as postischemic regulation of food intake.
Materials and methods

Animals, Food Intake, and Treatments
Adult male mice (3 to 6 months) were used in these experiments. The PPARa and PPARb KO mice (weight 22 to 25 g) were established on a C57BL/6J genetic background. For each mouse strain, appropriate colittermate controls (weight 22 to 24 g) were used. These mice were kindly supplied by Professor W Wahli, University of Lausanne (Tan et al, 2001) . The TNFa KO mice (strain Tnftm1Gkl, weight 21 to 23 g) (Pasparakis et al, 1996) , IFNg KO mice (strain B6.129S7-Ifng tm1Ts /J, weight 20 to 23 g) (Dalton et al, 1993) , and their wild-type (WT) counterparts (weight 21 to 24 g), all with a C57BL/6J background, were obtained from the Jackson Laboratory (Jackson-Bar Harbor, Maine, USA). The UCP2 KO mice (C57BL/6J, weight 19 to 21 g) and their WT colittermates (weight 19 to 22 g) were also used as described previously (de Bilbao et al, 2004) . All mice strains were backcrossed for at least 10 generations to ascertain the similarity of genetic background with WT mice. Mice were housed in individual cages for food intake and body weight studies, and had ad libitum access to standard laboratory diet and water. Food intake was calculated using the weight of food pellets from the previous day and subtracting the weight of the remaining pellets on the following day (measured at 0900). For all feeding experiments, a minimum of eight ischemic animals (eight WT and eight PPARb KO) and eight nonischemic animals (eight WT and eight PPARb KO) were used. Food intake baseline levels were recorded for 3 days before MCAO, and then food intake was quantified daily for 2 weeks. To evaluate the role of central NGF in food intake regulation, 200 ng of NGF 2.5S (Chemicon, Temecula, CA, USA) was injected on the lesion site in PPARb KO mice (n ¼ 8) 1 day after MCAO, as well as in sham-operated PPARb KO mice (n ¼ 8). This timing was determined by the maximal NGF effect on food intake observed in WT mice. Nerve growth factor was injected with a microsyringe (5 ml vehicle containing 200 ng of NGF per mouse) after the animals had been anesthetized with isoflurane. The food intake response was studied for 4 consecutive days. Additional experiments were performed in IFNg KO, TNFa KO, and UCP2 KO mice to explore the role of these proteins on food intake responses after MCAO (eight mice per group, as mentioned above). Because PPARb KO and UCP2 KO mice showed no hyperphagic phase response after MCAO, we also evaluated food intake in nonoperated PPARb KO and UCP2 KO mice after 24 h of fasting to examine whether a reduction in food intake induces a compensatory hyperphagia (n ¼ 8 for WT and KO groups).
Induction of Permanent Focal Cerebral Ischemia and Volume of the Infarct
We performed permanent MCAO in PPARa KO (n KO ¼ 6 and n WT ¼ 6) and PPARb KO (n KO ¼ 18 and n WT ¼ 16) mice. Animals were anesthetized intraperitoneally with xylazine (20 mg/kg)/ketamine (100 mg/kg) in 0.9% NaCl (100 ml/10 g body weight), the right temporoparietal region of the head was shaved and a 2-mm incision was made vertically between the orbit and the ear and the skull was exposed. Under an operating microscope, a small burr hole 1 mm 2 was made with a high-speed microdrill through the outer surface of the semitranslucent skull over the visibly identified medial cerebral artery at the level of the parietal cerebral artery. Saline was applied to the area throughout the procedure, to prevent heat injury. The inner layer of the skull was removed with fine forceps, the dura and the arachnoid were opened and right permanent MCAO was performed by electrocoagulation (by means of a small-vessel cauterizer), without damaging the brain surface. Permanent inhibition of cerebral blood flow after the lesion was assessed by visual inspection. If the brain surface was visibly damaged or if the middle cerebral artery bled owing to incomplete artery occlusion/ coagulation, the animal was not used for the study. The duration of the surgery did not exceed 15 mins in any case (de Bilbao et al, 2000) . After 4 days, the animals were perfused through the ascending aorta with a solution of 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.35) . Brains were removed and processed for paraffin embedding. Sections (7 mm) of the whole infarct area were cut with a microtome and collected on slides pretreated with 3-aminopropyltriethoxy-silane (Sigma, MO, USA). Sections were counterstained with cresyl violet for the histologic identification of the nuclear boundaries and periinfarct areas, and mounted in Eukitt. For each animal, quantification of the infarcted area was performed on the cresyl-violet-stained sections at five representative levels throughout the rostro-caudal extent of the lesion (A 0.26, À0.22, À0.40, À0.70, and À1.2 À4 mm relative to Bregma) (Franklin and Paxinos, 1997) . The rostro-caudal extent of the infarct was the same in both groups of mice. The infarcted area of each section was calculated by subtraction of healthy tissue areas of the contralateral from the ipsilateral side of the section to compensate for the effect of brain edema (Guegan et al, 1998) using a computerassisted image analyzing system (Software )Morphometry*, Samba 2005 TITN, Alcatel, Alcatel Grenoble, France). Volumes of infarct (mm 3 ) were calculated for each animal after integration of areas with the distance between each level (de Bilbao et al, 2004) .
To evaluate whether local alterations in cerebral vascular anatomy contribute to different susceptibility to injury in PPARb KO mice, an additional series of five WT and five KO mice were killed on day 4 (D4) after ischemia. Cerebral vasculature was studied in WT and PPARb KO mice (nonoperated and on D4 after ischemia) after intracardial perfusion with 0.9% NaCl solution followed by perfusion of a mixture of an equal proportion of gelatinous water (5%) and China ink (Sennelier, France) warmed at 401C (1 ml). Brains were removed and immersed for 24 h in 4% paraformaldehyde at 41C (Chen et al, 2005) . Cerebral vasculature was observed with a Zeiss stero zoom microscope. The absence of cerebral blood flow in the infarct area was assessed by transcranial measurements of CBF that were made using laser Doppler flowmetry Oxford Optronix Ltd (UK) just before and after MCAO. Animals were placed under a sterotactic head frame and then a fine needle probe (MNP110XP, 0.48 mm diameter) was lowered onto the temporal bone surface 0.5 to 1 mm dorsal to the opening giving access to the MCA and wetted with a small amount of physiologic saline. No preoperative or postoperative strain-related differences in CBF were observed and similar reductions in CBF were observed after MCAO in both strains.
Physiologic Parameters: Physiologic parameters including arterial blood pressure (Kent mouse tail blood pressure system RTBP2000, Kent Scientific Corporation, Torrington, USA), plasma glucose (using Roche Glucotrend Active, Rotkreuz, Switzerland), and hematocrit were measured daily in KO and WT mice (n ¼ 4 to 5) before MCAO and on D1 and D4 after injury. Body temperature was measured before, during, and after MCAO by a rectal thermometer probe (Ellab DM 852, Roeovre, Denmark). During surgery, mice were placed on a warm mat and rectal temperature was measured. In the preoperation period, rectal temperature was similar in WT (38.01C7 0.11C) and PPARb KO (38.01C70.11C) mice and remained stable after the operation. Daily body temperature was measured at 1030.
In situ Hybridization for PPARb mRNA Expression in PPARb KO and WT Mice after MCAO On D4 after injury, the expression of PPARb mRNA was determined by in situ hybridization in WT (n ¼ 4) and PPARb KO (n ¼ 4) mice and compared with their nonoperated counterparts. Mice were anesthetized with 0.3 ml of a mixture containing 40 mg/ml ketamine and 2 mg/ml xylazine and were immediately perfused intracardially with 20 ml of ice-cold isotonic saline followed by 100 ml of a 4% paraformaldehyde solution. At the end of the perfusion, brains were removed and kept in 4% paraformaldehyde for 3 to 4 days and then transferred to a solution containing paraformaldehyde and sucrose (10%) for 12 h. Sections (25 mm thick) were cut with a sliding microtome (Microtome HM 440E, Microm) and mounted onto slides. In situ hybridization histochemistry was performed using a biotin-labelled oligonucleotide PPARb probe for mRNA (mouse 61 to 111, 5 0 -atgggtgacg gagccccgga gctcaatggg ggaccagaac acacgcttcc-3 0 , and its complementary sequence as a negative control) to detect PPARb (Catalys, Wallisellen, Switzerland). Briefly, 9 pmol/ml of biotin-labelled oligonucleotide was incubated for 2 h at 371C in a hybridization solution (5 mol/L NaCl, 10 Â PE (0.5 M Tris, 1% sodium pyrophosphate, 2% polyvinyl pyrrolidone, 2% Ficoll, SOmMEDTA) buffer, 50% dextran sulfate, 30% formamide) in an OmniSlide Thermal Cycler. After incubation, the slices were washed and biotin labelling was detected using avidin peroxidase complex with diaminobenzidine enhanced by nickel. The specificity of the antisense riboprobe was determined by the absence of a positive signal in sections hybridized with the sense probe.
PCR Determination of mRNAs in PPARb KO and WT Mice after MCAO
For PPARb and UCP2 mRNA determinations, ischemic hemispheres were dissected and total RNA was isolated as described previously (Arsenijevic et al, 2000a) . Brain tissues were collected (n ¼ 4 per group) at 1, 4, and 7 days after MCAO from WT and PPARb KO mice, as well as from nonoperated control counterparts. In addition, we assessed mRNA expression for neuropeptide Y (NPY), melanin concentrating hormone (MCH), and orexin, three hormones involved in food intake. For this purpose, the whole hypothalamus was dissected out and the RNA was isolated. The RNA was treated with DNase and then reverse transcribed (Promega, Catalys, Wallisellen, Switzerland). Thereafter, a semiquantitative PCR (Invitrogen, Basel, Switzerland) was performed and the product separated by gel electrophoresis containing ethidium bromide. The bands were then quantified using the Scion Image program (Scion Corporation, MD, USA). Each sample was normalized with its glyceraldehyde 3-phosphate dehydrogenase content. The primers used were as follows: UCP2 (sense 5 0 -TAC CAG AGC ACT GTC GAA GCC-3 0 , antisense 5 0 -AGT CCC TTT CCA GAG GCC C-3 1997) . All values for the semiquantitative RT-PCR expression of a gene were obtained after normalizing for glyceraldehyde 3-phosphate dehydrogenase. The level of PPARb and UCP2 was also quantified using real-time PCR (Berthiaume et al, 2004) . Lesioned and nonlesioned brain hemispheres (n ¼ 4 for each group of mice) were removed on D4 after MCAO and stored in RNA later (Ambion, TX, USA) at 41C. Brain mRNA was extracted using the Trizol RNA extraction method. RNA concentration was estimated from absorbance at 260 nm and RNA was transcribed using Expand reverse transcriptase (Roche Diagnostics, Laval, QC, Canada). The mRNA expression level was quantified using quantitative fluorescent realtime PCR (Corbett Research, New South Wales, Australia). Amplification and detection of target mRNA were performed with Platinum Taq polymerase and the intercalating dye SybrGreen I (Berthiaume et al, 2004) . The mRNA levels of PPARb and UCP2 were normalized with betaactin. The primers used were as follows: PPARb, sense 5 0 -AGTTCTTGCGCAGTATCCG-3 0 , antisense 5 0 -AGTGTTGT GAGTGGCTCTAG-3 0 ; UCP2, sense 5 0 -TTC TCC TGC GGT CCG GAC ACA ATA-3 0 , antisense 5 0 -TTGA CTC TCC CCT TGG ATC TGC AG-3 0 ; and beta-actin, sense 5 0 -CTC TAG ACT TCG AGC AGG AG-3 0 , antisense 5 0 -AGA GTA CTT GCG CTC AGG AG-3 0 . The primers were designed using the Vector NTI program. For both experiments, gene expression represented the percentage obtained by comparing operated hemispheres to control hemispheres of nonoperated mice.
Brain Cytokine Levels after MCAO in PPARb KO and WT Mice
The levels of TNFa, IFNg, and NGF were measured by immunoassay in the brains of operated and nonoperated PPARb KO and WT mice (n KO ¼ 8 and n WT ¼ 8, each group consisting of four ischemic and four nonoperated animals) on D1 and D4 after MCAO. Brains were aseptically removed and immediately placed on dry ice. The ischemic hemispheres of operated mice and hemispheres of nonoperated mice were put in CHAPS solution and homogenized. The supernatant was collected and frozen at À201C (Arsenijevic et al, 2000a) . Cytokines TNFa and IFNg, as well as NGF, were measured using immunoassay kits from Amersham and Catalys (Wallisellen, Switzerland). To study possible interactions between these three cytokines, NGF levels were also assessed in IFNg KO and TNFa KO mice, and in the corresponding WT mice 1 day after ischemia (n KO ¼ 8 and n WT ¼ 8, each group consisting of four ischemic and four nonoperated animals).
Lipid Peroxidation
The levels of malondialdehydes (MDA), indicators of endogenous peroxidation, were measured in PPARb KO and WT mice on D1 and D4 after MCAO. Mice were anesthetized and perfused intracardially with saline solution. After perfusion, the brain was removed and the ipsilateral and contralateral whole hemispheres of operated and nonoperated mice were washed three times in ice-cold Tris-HCl 20 mmol/L buffer (pH 7.4). They were then gently homogenized for 1 min in a glass tissue grinder (Wheaton, Millville, NJ, USA) in 4 ml of the same buffer. Homogenates were centrifuged at 3,200g for 10 mins at 41C and the supernatant was processed for MDA levels using a lipid peroxidation assay (de Bilbao et al, 2004) . To prevent sample oxidation, 0.5 mmol/L butylated hydroxytoluene (Sigma Chemicals, St Louis, MO, USA) was added to the tissue homogenate. Optical density was measured at 586 nm using a spectrophotometer (Dynatech, Chantilly, VA, USA). Changes in oxidative stress were assessed in brain homogenates in nonoperated (n KO ¼ 8 and n WT ¼ 8) and operated (n KO ¼ 8 and n WT ¼ 8) PPARb KO and WT mice. For each group of mice, MDA levels of the operated brain hemisphere were compared with those of the hemisphere of nonoperated animals (de Bilbao et al, 2004) .
Glutathione Levels
Brain homogenates from WT and PPARb KO mice, subjected or not to ischemia (1 and 4 days after ischemia) (n ¼ 8 per group), were processed as described previously for reduced GSH (de Bilbao et al, 2004) . Reduced GSH levels were measured using a method based on the formation of a chromophoric product resulting from the reaction of 5,5 0 -dithiobis-(2-nitrobenzoic acid) (Sigma Chemicals, St Louis, MO, USA) and GSH (Sigma, Buchs, Switzerland). For each group of mice, we compared the operated brain hemisphere with the nonoperated hemisphere of control animals. To evaluate whether IFNg administration influences oxidative stress regulation in ischemic PPARb KO mice, these animals and their WT counterparts (n ¼ 8 for each group) were pretreated with IFNg antibody 18 h before MCAO and were killed 4 days later. Interferon-gamma antibody (ATCC HB170 from American Type Culture Collection, MD, USA, provided by C Yesin, CMU, Geneva, Switzerland) was injected at 50 mg per mouse intraperitoneally (Arsenijevic et al, 2000a) . Levels of MDA and GSH were also assessed in these mice as described above.
Immunohistochemistry and Double Staining Experiments
Frozen coronal sections (25 mm) from operated (1 and 4 days after ischemia) and nonoperated WT and PPARb KO mice (n ¼ 4 for each group) were processed for MnSOD immunostaining using sheep anti-human MnSOD (1/100; Calbiochem, San Diego, CA, USA) and rabbit anti-sheep immunoglobulins (Dako, CA, USA) as the secondary antibody. Immunohistochemistry of MnSOD was performed on nonoperated and operated (1 and 4 days after MCAO) WT and PPARb KO mice. We also tested MnSOD immunostaining 4 days after MCAO in WT and PPARb KO mice treated with 200 ng NGF 2.5S on the lesion site 1 day after MCAO. Immunohistochemistry of PPARb was performed using an anti-PPARd rabbit polyclonal antibody (PA1-832) from Affinity Bioreagents (Golden, CO, USA) and visualized by a secondary goat anti-rabbit fluorescein isothiocyanate (Nordic Immunology, Tiburg, The Netherlands). To label astrocytes, microglia, macrophages, oligodendrocytes, and neuronal cells, mouse polyclonal anti-glial fibrillary acidic protein clone GA5 (1/400; Sigma, MO, USA), rabbit polyclonal anti-Iba1 (1 mg/ml; kindly provided by Professor Y Imai, National Center of Neurology and Psychiatry, Japan), rat anti-mouse F4/80 for macrophage (1/200; Serotec, Oxford, UK), anti-CNPase (2 0 3 0 cyclic nucleotide 3 0 phosphodiesterase) (1/200; Sigma, MO, USA), and the mouse anti-neuronal nuclei monoclonal antibody (NeuN) (1/1,000; Chemicon, Temecula, CA, USA) were used. The glial fibrillary acidic protein, anti-Iba1, anti-macrophages, and NeuN antibodies were detected using Alexa Fluor 546 rabbit anti-mouse (Molecular Probes, Eugene, OR, USA), goat anti-rabbit immunoglobulins Alexa Fluor 568 (Molecular Probes), goat anti-rabbit fluorescein isothiocyanate, goat anti-rat fluorescein isothiocyanate (Nordic Immunology), and goat anti-mouse immunoglobulins linked to AMCA (9-amino-6-chloro-2-methoxyacridine) (Dako). Negative controls included deletion of the primary or secondary antibody. Photomicrographs of immunofluorescent staining were constructed using the Axioskop 2 and the software Axiovision.
Statistical Analysis
Results are expressed as means7standard error of the mean (s.e.m.). Differences between groups were assessed using a two-way ANOVA followed by the Bonferroni post hoc test. Po0.05 was considered significant.
Results
Physiologic Parameters before and after MCAO Arterial pressure, plasma glucose, hematocrit levels, and body temperature before and after MCAO on D1 and D4 were not significantly different between WT and PPARb KO mice at a given time point, as shown in Table 1 . There were no significant differences between WT and KO mice between the different days (Table 1) . After MCAO, both WT and PPARb KO mice showed an absence of cerebral blood flow in the infarct area.
PPARb and UCP2 mRNA Expression in WT and PPARb KO Mice after MCAO
The expressions of PPARb and UCP2 mRNAs in response to ischemic brain injury were determined by semiquantitative RT-PCR. Peroxisome prolifera- Hematocrit, plasma glucose, body temperature, and arterial pressure were measured in wild-type (WT) and PPARb knockout (KO) mice before ischemia, and then on days 1 (D1) and 4 (D4) after MCAO. No significant differences were observed between WT and KO mice on any given day, and there were no significant differences between days in WT and KO. Data are means7s.e.m. of four to five animals per group. MCAO: middle cerebral artery occlusion; PPARb: peroxisome proliferator-activated receptor b.
Role of PPARb in focal cerebral ischemia D Arsenijevic et al tor-activated receptor b mRNA was significantly upregulated (45% to 58%, Po0.001) in the ischemic hemispheres of WT mice compared with nonoperated animals on D1, D4, and D7 after MCAO ( Figure  1A) . As expected, PPARb mRNA was not detected in PPARb KO mice ( Figure 1A) . Uncoupling protein 2 mRNA was also significantly increased (30% to 70%, Po0.001) in the ischemic hemispheres of WT mice on D1, D4, and D7 after MCAO ( Figure 1B) . Interestingly, no significant induction of UCP2 mRNA was observed in the ischemic hemispheres of PPARb KO mice (10% to 14%, P40.05) compared with nonoperated animals after MCAO ( Figure 1B) . Quantitative fluorescent real-time PCR also indicated that PPARb and UCP2 were induced in WT mice on D4 after MCAO (112%712% and 91%7 10%, respectively) but not in PPARb KO mice. In situ hybridization experiments also revealed induction of PPARb mRNA in the periinfarct area on D4 after MCAO in WT mice ( Figure 1C ) but not in PPARb KO mice (not shown). No labelling was observed in the contralateral hemisphere of WT mice. Induced PPARb mRNA labelling occurred in oligodendrocytes and neurons in the border of the necrotic zone (data not shown) (Woods et al, 2003) . Immunofluorescent staining of PPARb showed that PPARb protein was induced in the periinfarct area of WT mice but not in PPARb KO mice 4 days after MCAO ( Figures 1D and 1E ).
Infarct Size after MCAO is Increased in PPARb KO Mice
The infarct volume was quantified on D4 after permanent MCAO in WT and PPARb KO mice, a time at which PPARb mRNA was markedly increased in the periinfarct area of WT mice ( Figure  1A ). Infarct volume was increased two-fold in PPARb KO mice (10.970.2 mm 3 , n ¼ 18) when compared with WT mice (5.371.3 mm 3 , n ¼ 16) (Po0.001) ( Figure 2) . No difference was observed in the vascular system (organization of the circle of Willis, position and diameters of the main cerebral arteries) between WT and KO mice. At 4 days after MCAO, no revascularization was observed on the surface of the injured hemisphere in both mice strains (data not shown). . Gene expression is reported as the percentage of increase observed in operated hemispheres compared with control hemispheres of nonoperated mice. In WT mice, PPARb and UCP2 mRNAs were significantly induced after ischemia (Po0.001). The increases in PPARb and UCP2 mRNAs in the operated hemispheres were significantly higher in WT than in KO mice at all time points (Po0.001). In PPARb KO mice, PPARb mRNA was not detected. Each value is expressed as mean7s.e.m. (***Po0.001, **Po0.01). (C) In situ hybridization localization of PPARb mRNA. Note that PPARb is found at the periphery of the lesion site, as indicated by the arrow; PPARb mRNA was found in neurons and oligodendrocytes. (D) Immunofluorescent staining for PPARb on D4 after MCAO in WT mice and (E) PPARb KO mice. In WT mice, labelled cells were found in the cortical periinfarct area. No labelling was observed in PPARb KO mice (scale bar: 40 mm (C), 15 mm (D, E)).
Role of PPARb in focal cerebral ischemia D Arsenijevic et al Importantly, this effect was specific for PPARb because there was no significant difference in lesion volume between PPARa KO mice and their WT counterparts (5.671.6 and 5.871.1 mm 3 , respectively, n ¼ 6 per group) (P40.05).
Altered Lipid Peroxidation and Glutathione Levels in PPARb KO Mice after MCAO and their Regulation by IFNc
In both groups of mice, a significant increase in MDA levels was observed in the ischemic brains when compared with the nonoperated mice (Table 2) . Moreover, PPARb KO mice had significantly higher levels of MDA than WT mice (Table 2) . Reduced GSH levels were significantly decreased in the brains of WT and PPARb KO mice on D1 and D4 after MCAO (Table 2) . On D4 after ischemia, PPARb KO mice had significantly lower levels of GSH than WT mice (Table 2) .
Administration of IFNg antibody 18 h before MCAO led to a significant reduction of MDA increase and GSH loss on D4 after ischemia in both WT and PPARb KO mice when compared with nontreated ischemic mice, suggesting that oxidative stress is mediated by IFNg in both types of mice. When the antibody was administered to mice that did not undergo MCAO, it did not have any effect on MDA or reduced GSH brain levels compared with nontreated mice. MDA and reduced GSH levels were measured in ischemic and nonoperated wild-type (WT) and peroxisome proliferator-activated receptor b (PPARb) knockout (KO) mice on days 1 (D1) and 4 (D4) after MCAO. Additional PPARb KO and WT mice were also pretreated with interferon-gamma antibody (anti-IFN) 18 h before MCAO. Asterisks in the first two columns indicate comparisons between nonoperated (control) and operated animals of the same genotype. Daggers correspond to comparisons between anti-IFN-treated and nontreated mice on D4 after ischemia. In the last column, Bonferroni test after ANOVA indicates a statistical difference between WT and PPARb KO mice with the same treatment (*Po0.05, **Po0.01, ***Po0.001, and w Po0.001). Data are means7 s.e.m. It should be noted that the comparison of results between operated and nonoperated mice may require sham-operated controls. However, several previous reports have demonstrated that most biochemical and morphologic markers used in the present study are only marginally affected in sham-operated animals compared to animals with cerebral ischemia (Mizui et al, 1992; Suzuki et al, 1999; Candelario-Jalil et al, 2001; Pratico et al, 2002) . MDA: malondialdehydes; GSH: glutathione; MCAO: middle cerebral artery occlusion; NS: nonsignificant. Tumor necrosis factor alpha was significantly induced in the brain of WT mice on D1 after MCAO (9078 pg/ml, Po0.001), and returned to basal levels on D4 (1673 pg/ml) compared with nonoperated WT mice (1974 pg/ml) ( Figure 3A) . In contrast, PPARb KO mice showed no induction of TNFa on either day after MCAO (1573 and 1873 pg/ml for D1 and D4, respectively) when compared with nonoperated animals (1774 pg/ml, P40.05 ( Figure 3A) .
Similarly, NGF levels were markedly increased on D1 (22177 pg/ml) (Po0.001) and D4 (9374 pg/ml) (Po0.01) after MCAO in the brain of WT mice when compared with nonoperated animals (21710 pg/ml) ( Figure 3B) . Again, the upregulation of NGF levels was completely ablated in PPARb KO mice (247 7 pg/ml on D1 and 3275 pg/ml on D4) when compared with nonoperated mice (3072 pg/ml) ( Figure 3B ).
Interferon-gamma was significantly increased in the brains of both WT and PPARb KO mice on D1 after ischemia (21178 and 357715 pg/ml, respectively) when compared with nonoperated animals (12573 and 13974 pg/ml, respectively) (all comparisons Po0.001) ( Figure 3C ). At 4 days after ischemia, IFNg was still significantly increased in PPARb KO mice compared with nonoperated animals (24276 and 13974 pg/ml, respectively) (Po0.001) but returned to basal levels in WT mice ( Figure 3C) . Interestingly, and although IFNg basal levels did not differ between nonoperated WT and PPARb KO mice, IFNg levels at D1 and D4 were significantly higher in KO (D1: 69%, Po0.01; D4: 74%, Po0.01) than in WT mice ( Figure 3C ).
MnSOD is Reduced in PPARb KO mice after MCAO: Reversal by NGF Treatment
Because MnSOD is thought to be the first line of defense against oxygen toxicity, we also examined its presence in WT and PPARb KO mice before and after MCAO. No immunostaining was detected in WT and PPARb KO mice before MCAO. Double Figure 3 Levels of (A) TNFa, (B) NGF, and (C) IFNg as determined by immunoassay in the hemispheres of nonoperated WT (WTc) and PPARb KO (KOc) mice and in the ischemic hemispheres of WT and PPARb KO mice on D1 and D4 after MCAO. (A) The levels of TNFa were significantly increased on D1 after ischemia in WT mice (Po0.001) but not in PPARb KO mice (P40.05) (WTc and KOc, respectively). (B) The levels of NGF were significantly increased on D1 and D4 after ischemia in WT mice (Po0.001 and Po0.01, respectively) but not in PPARb KO mice (P40.05). (C) The levels of IFNg were increased on D1 after ischemia in WT mice compared with nonoperated WT animals (Po0.001). In PPARb KO mice, IFNg was also significantly increased on D1 and D4 after ischemia compared with both nonoperated PPARb KO mice (Po0.001) and WT animals (Po0.001). Each value is expressed as mean 7s.e.m. (n ¼ 4 mice per group) (**Po0.01, ***Po0.001). staining experiments revealed MnSOD-positive neurons and astrocytes in WT mice at D1 and D4 after MCAO. Positive immunostaining was observed in the striatal border and the neocortical border zones of the periinfarct area. In contrast, PPARb KO mice did not show any staining at the same time period ( Figure 4) . Importantly, treatment of PPARb KO mice with NGF 1 day after ischemia resulted in detection of MnSOD labelling at D4 after lesion (Figure 4) . In Figure 4 , the punctate immunostaining indicates the mitochondrial distribution of the protein in both groups of mice. Treatment with NGF was also Figure 5 Food intake responses in PPARb KO, IFNg KO, TNF KO, and UCP2 KO mice after MCAO. (A) Food intake responses to MCAO in WT and PPARb KO mice. Nonoperated PPARb KO mice (KOc) did not differ in food intake compared with their WT counterparts (WTc) (P40.05). On D3 to D5 after MCAO, WT (WTisch) but not PPARb KO mice (KOisch) showed significant hyperphagia compared with nonoperated mice (WTc) (**Po0.01). (B) Effect of NGF treatment on food intake of PPARb KO mice after MCAO. Administration of NGF (200 ng on the lesion site 1 day after MCAO) induced a hyperphagic response on D3 to D4 after ischemia in PPARb KO mice (KOisch þ NGF) (***Po0.001). (C) Food intake after 24 h fasting in WT, PPARb KO, and UCP2 KO mice. As observed for WT mice, PPARb KO and UCP2 KO mice were able to respond with a hyperphagic state 1 day after fasting (KOf) compared with their controls (KOc) (**Po0.01 for each group). (D) Food intake responses to MCAO in IFNg KO mice. The IFNg KO mice (KOisch) did not show significant post-MCAO hypophagia compared with WT operated mice (WTisch). On D0 to D2, IFNg KO mice (KOisch) ate significantly more than WT mice (WTisch) (***Po0.001). The IFNg KO mice showed significant hyperphagia after MCAO (KOisch) when compared with nonoperated mice (KOc) (***Po0.001). (E) Food intake responses to MCAO in TNFa KO mice. The TNFa KO mice (KOisch) showed significant hyperphagia after MCAO (KOisch) when compared with nonoperated mice (KOc) (***Po0.001). (F) Food intake responses to MCAO in UCP2 KO mice. The significant hyperphagia observed in WT mice after MCAO (WTisch) (**Po0.01) did not occur in UCP2 KO mice (KOisch) (P40.05). Each value is expressed as mean7s.e.m.
Role of PPARb in focal cerebral ischemia D Arsenijevic et al associated with decreased infarct size in PPARb KO mice (from 9.370.6 to 6.870.4 mm 3 ) (Po0.05, n ¼ 8).
Lack of Hyperphagic Response to MCAO in PPARb KO
Mice: Involvement of NGF, IFNc, and UCP2, but not TNFa
The PPARb KO and WT mice show acute hypophagia on the day of MCAO intervention and then regain appetite. The compensatory hyperphagic phase, lasting from D3 to D5, in WT mice (n ¼ 8, Po0.01) did not occur in PPARb KO mice ( Figure 5A ). Injection of NGF on the lesion site of PPARb KO mice 1 day after MCAO resulted in significant hyperphagia from D3 to D4 after ischemia (Po0.001) ( Figure 5B) . In contrast to the patterns of food intake observed after MCAO, both WT and PPARb KO mice displayed a significant hyperphagic response 1 day after a 24-h period of fasting (n ¼ 8, Po0.01) ( Figure 5C ).
Because altered levels of TNFa, IFNg, and UCP2 were observed in PPARb KO mice after ischemia, food intake was also measured in TNFa KO, IFNg KO, and UCP2 KO mice. Interferon-gamma KO mice did not show hypophagia from D0 to D3 after MCAO when compared with WT ischemic mice (P40.05), but rapidly entered a hyperphagic state compared with WT ( Figure 5D ). During the period D0 to D2 after MCAO, IFNg KO mice ate significantly more than WT mice (Po0.001) ( Figure 5D ). Like their WT counterparts, TNFa KO and IFNg KO mice showed significant hyperphagia after MCAO compared with their nonoperated controls (from D3 to D5, and D2 to D4, respectively) (Po0.001) ( Figures 5D and 5E ). In contrast, UCP2 KO mice did not show significant hyperphagia after MCAO when compared with WT (P40.05) ( Figure 5F ), but were able to show a significant hyperphagic response 1 day after 24 h fasting (n ¼ 8, Po0.01) ( Figure 5C ). In all animals, the body weight followed a parallel time course to that of food intake (data not shown).
NPY Expression is Decreased in PPARb KO Mice after MCAO
Basal levels of neuropeptide mRNAs (NPY, orexin, and MCH) did not differ between PPARb KO and WT mice (data not shown). The expression of the three neuropeptides showed significant increases 4 days after MCAO in WT mice when compared with nonoperated animals (NPY: 110%75%; orexin: 60%72%; MCH: 69%74%; n ¼ 4 and Po0.001 for the three groups) ( Figure 6 ). However, NPY mRNA induction in PPARb KO mice was markedly attenuated (22%72%, Po0.001) compared with WT mice (Figure 6 ). This was not the case for orexin (51%7 4%, n ¼ 4) and MCH (57%74%, n ¼ 4) mRNAs, which showed a similar post-MCAO increase in both PPARb KO and WT mice ( Figure 6 ).
Discussion
The major finding of this study is that the deletion of PPARb gene in mice dramatically exacerbated the deleterious consequences of focal cerebral ischemia. The enhanced susceptibility to MCAO was revealed by a 50% increase in lesion volume in the PPARb KO mice compared with their WT counterparts. The greater sensitivity observed after MCAO was specifically related to PPARb absence because the infarct size was similar in PPARa WT and KO mice. This latter finding is in agreement with a recent study that clearly showed that PPARa receptor deficiency is not associated with an increased susceptibility to focal cerebral ischemia in mice (Deplanque et al, 2003) . Although all three PPAR types are present in the brain, PPARb receptor is the most abundant in cortical cells (Cullingford et al, 1998) , further supporting an involvement of PPARb activation in neuroprotective mechanisms against focal cerebral ischemia. However, and as is the case for all studies comparing WT with KO mice (Durum and Muegge, 1998; Samson and Taylor, 2005) , our study does not eliminate the possibility that PPARb regulation of MCAO lesion size could be indirect. Yet, our model showed that PPARb deficiency results in increased lesion size, indicating that lack of PPARb could not be compensated.
This increased susceptibility to MCAO in PPARb KO mice was accompanied by massive changes in both antioxidant mechanisms and cytokine activation. The increase of oxidative injury in these mice was indicated by the upregulation of MDA content and reduction of MnSOD and reduced GSH levels, two classical brain antioxidants. Importantly, our results also show that, in contrast to WT mice, the transcript of UCP2, a regulator of reactive oxygen species (Arsenijevic et al, 2000b) , is not upregulated in PPARb KO mice after ischemia. In conjunction with previous studies showing that activation of PPARs may induce UCP2 mRNA expression in various tissues (Aubert et al, 1997; Wang et al, 2003) , this observation implies that UCP2 may require PPARb to be induced in brain tissue after ischemic injury. Altered cytokine levels may also contribute to the deleterious consequences of cerebral ischemia in PPARb KO mice. In particular, TNFa and NGF, two macrophage cytokines known to be involved in the acute phase of brain ischemic tolerance (Guegan et al, 1998; Scherbel et al, 1999) , are not induced after MCAO in the brain of PPARb KO mice. In contrast, the levels of the proinflammatory lymphocyte cytokine IFNg were abnormally elevated in the brain of PPARb KO mice after MCAO, suggesting that PPARb may inhibit the induction of this inflammatory cytokine. Altogether, these results imply that PPARb may participate in the regulation of both macrophage and lymphocyte cytokines. The lack of NGF induction after MCAO in PPARb KO mice cannot be explained by the absence of TNFa because TNFa KO mice were still able to induce NGF (data not shown). It remains to be determined whether the higher amounts of IFNg found in the PPARb KO mice could partially explain the ablated NGF because IFNg has been shown to block NGF secretion in neonatal astrocyte culture but not quiescent astrocytes (Awatsuji et al, 1995) . Interestingly, our data also provide further evidence indicating that the oxidative status of PPARb KO mice after MCAO may be mediated by altered cytokine levels. In fact, IFNg antibody administered before MCAO to PPARb KO mice reduced MDA increase and GSH loss in the mice. Consistent with previous observations in this field, acute NGF administration after ischemia led to a substantial decrease of infarct volume in WT mice (Semkova and Krieglstein, 1999) . Moreover, the decreased infarct volume and upregulation of MnSOD expression observed in the brain of NGF-treated PPARb KO mice after ischemia suggest that the reduced availability of NGF may be partly at the origin of the higher vulnerability to cerebral ischemia in PPARb KO mice (Guegan et al, 1999) .
Besides the importance of PPARb in the regulation of central ischemic damage, another important finding of the present study is that PPARb is also involved in the regulation of food intake after MCAO. The rapid hyperphagic phase induced in WT mice after MCAO was not present in PPARb KO mice, suggesting that the cellular signalling involved in MCAO-induced hyperphagia is not functional in PPARb KO mice. Because NGF treatment can restore hyperphagia in these mice, a role for NGF in mediating the hyperphagic response after ischemia is strongly suggested. This finding is consistent with a previous study showing that NGF induces hyperphagia when administered after hypothalamic damage (Berger et al, 1973) . The specific role of PPARb in MCAO-induced hyperphagia may also involve NPY, as indicated by the blunted NPY induction in PPARb KO mice after ischemia. Whether NGF is necessary for NPY expression, as suggested by other studies (Verge et al, 1995) , remains to be determined. In agreement with previous observations on TNFa and IFNg anorexic effects (Arsenijevic et al, 2000b; Langhans, 2000) , the fact that ischemic TNFa KO and IFNg KO mice entered in a hyperphagic state suggests that these cytokines are not required for hyperphagia after MCAO. In addition, the hyperphagic phase observed in these two genotypes after MCAO is consistent with their associated increased NGF levels. Thus, the absence of TNFa observed in PPARb KO mice should not play a major role in the lack of hyperphagic response observed in these mice. In contrast, because IFNg KO mice ate significantly more than WT mice the first 2 days after MCAO, it is possible that the elevated levels of this anorexic cytokine in PPARb KO mice could partly explain the lack of hyperphagia after MCAO (Arsenijevic et al, 2000b) . Because UCP2 KO mice did not display hyperphagia after cerebral ischemia, the absence of UCP2 induction after MCAO could also contribute to the lack of hyperphagia in PPARb KO mice. Taken together, these new data indicate that induction of PPARb and UCP2 expression may be critical in the molecular mechanisms regulating food intake after MCAO. This regulation of food intake is MCAO specific because PPARb KO and UCP2 KO mice are still able to display a hyperphagic response after a period of fasting. The close relationship between PPARb and UCP2 is further highlighted in that they are expressed in the same hypothalamic nuclei known to regulate food intake (Richard et al, 1998; Woods et al, 2003) .
Although our data indicate that PPARb is involved in infarct size and regulates hyperphagic response after MCAO, the present data do not support a causal relationship between these two phenomena. Middle cerebral artery occlusion induces hypophagia followed by hyperphagia and then a return to basal food intake levels in balb/c, C57bl/J6, sv129, b6, and CFW mice strains (Arsenijevic et al, 2003) . Several lines of evidence indicate that the size of the infarct is not necessarily related to hyperphagia. First, an increased infarct volume in the PPARb KO mice was associated with lack of hyperphagia. Second, IFNg KO mice have a smaller infarct size than their WT counterparts (data not shown), yet they showed a more rapid onset of hyperphagia. In contrast, our previous work revealed a smaller infarct size in UCP2 KO mice than their WT counterparts in the absence of hyperphagia (de Bilbao et al, 2004) . Permanent distal MCAO model affects the cerebral cortex, whereas food intake response is traditionally thought to be related to the hypothalamus. However, numerous earlier contributions showed that food intake is a complex process involving several cortical areas (Hinton et al, 2004; Kaye et al, 2005; Rolls, 2005) . Similarly, lesions in the cerebral cortex may decisively influence food intake (Modo et al, 2000) . Furthermore, a recent contribution showed that altered eating behaviors are mostly related to the neural circuits between the cerebral cortex and appetite-regulating centers located in the hypothalamus (Rolls, 2005) . Alternatively, appetite regulation may also be influenced by acute inflammatory phenomena related to the activation of cytokines/eicosanoids (Langhans, 2000) . Although our data do not provide a definite conclusion about the etiology of feeding disorders in PPARb KO mice, they strongly support a predominant role of cytokine and humoral immunity mechanisms in this context.
To our knowledge, this is the first study addressing the role of PPARb in three main biologic events associated with cerebral ischemia, namely morphologic changes, activation of antioxidant and inflammatory mechanisms, as well as food intake. The above-discussed findings clearly suggest a central role of PPARb in neuroprotection against focal cerebral ischemic damage, as well as in the molecular mechanisms involved in the associated antioxidant, inflammatory, and food intake responses. It may orchestrate energy balance and inflammation during MCAO. Based on these observations, a pharmacological modulation of PPARb, such as that induced with the use of specific PPARb agonists (Li et al, 2004) , could represent a relevant therapeutic possibility in the field of cellular protection after stroke.
